Welcome to the 2nd Inflammasome Therapeutics Summit

Built with Inflammasome Therapeutics, GSK, and Novartis, the 2nd Inflammasome Therapeutics Summit is the only industry focused meeting dedicated to solving the challenges of targeting the inflammasome to develop clinically effective therapeutics. Bringing together over 200 of the industry’s leading experts to one virtual meeting, this event will gather pharma, biotech and academia to overcome the challenges and opportunities the inflammasome field is facing.

This year’s summit will once again unite thought leaders in inflammasome drug development to discuss clinical developments in 2019/2020, share novel inflammatory pathways outside of NLRP3, the development of the NLRP3 pathway and translate these into clinically effective therapeutics.

The Inflammasome Therapeutics Summit is the industry’s definitive inflammasome drug development conference. Dedicated to overcoming challenges in developing clinically effective inflammasome therapeutics, this comprehensive discussion and networking forum will enable you to:

Optimize your clinical trial design and hear the latest readouts from the clinic
Deepen your biological understanding of how the inflammasome is activated and regulated at a cellular level
Identify novel inflammasome pathways focussing not only on NLRP-3 but looking beyond and outside of this exciting pathway
Determine which diseases the inflammasome is driving and therefore which have the most therapeutic potential commercially and clinically


Across two parallel tracks of learning and 32 speakers, don’t miss this unique opportunity to be part of the online discussion. Sharing hotly anticipated case studies and lessons learned exclusively focused on the discovery and translational challenges, we bring you the leading and unmissable Inflammasome Therapeutics Summit.

Testimonials from previous Hanson Wade attendees:

The Inflammasome Therapeutics Summit was a terrific way to catch up with both academic pioneers and the breadth of pharma research in this rapidly emerging area of innate immunology that underlies many, if not most, 21st century chronic diseases
Tufts University

Great meeting to engage with all the leaders in the field. The speed networking session was particularly productive!
Ventus Therapeutics

The overall high quality of the science sessions, followed by reserved time for networking, gave an opportunity for establishing many new connections and interesting science discussions.

Snapshot of 2020 Attendees:

Inflammasome companies attending

2020 Partners Included: